Older patients, TP53 mutation fusion or MLL rearranged, which are independent adverse prognostic factors for AML patients (2), had higher risk scores, and those with RUNX1-RUNX1T1, a favorable fusion gene, had lower risk scores. This evidence concerns the gene RUNX1T1 and acute myeloid leukemia.